All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Prophylactic GvHD treatment with ATLG in patients with myelofibrosis
|
Treatment with antithymocyte globulin (ATG) or anti-T-lymphocyte globulin (ATLG) can reduce the incidence and severity of graft-versus-host disease (GvHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) from related or unrelated donors; however, data on the use of ATG/ATLG in patients with myelofibrosis are limited.1 Results from a retrospective analysis to assess the impact of ATLG on outcomes of patients with myelofibrosis undergoing allo-HSCT were published in Bone Marrow Transplantation by Rathje, et al.1 |
| Key learnings1 |
|
The study found that the cumulative incidence of acute GvHD (aGvHD) Grade II–IV (30% vs 56%; p < 0.001), aGvHD Grade III–IV (20% vs 25%; p = 0.01), and severe chronic GvHD (cGvHD; 7% vs 18%; p = 0.04) was lower in the ATLG cohort (n = 469) vs the no ATLG cohort (n = 238), while the incidences of mild-to-severe cGvHD were similar (49% vs 50%; p = 0.52). |
|
ATLG treatment was associated with a notable improvement in the estimated GvHD-free and relapse-free survival (GRFS) at 3 years (53% vs 47%; p = 0.04) and 6 years (45% vs 37%; p = 0.02), particularly in patients with matched related or unrelated donors. |
|
Despite the benefits in reducing GvHD and improving GRFS, there were no significant differences between the ATLG and no ATLG cohorts in terms of estimated overall survival at 6 years (64% vs 60%; p = 0.53), cumulative incidences of relapse at 6 years (12% vs 15%; p = 0.62), and non-relapse mortality at 1 year (20% vs 19%; p = 0.80) and 3 years (27% vs 29%; p = 0.55). |
|
These findings suggest that ATLG treatment can improve GRFS, mainly driven by a reduction in aGvHD, in patients with myelofibrosis undergoing allo-HSCT with a matched related or unrelated donor. |
- Rathje K, Gagelmann N, Salit RB, et al. Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation. Bone Marrow Transplant. 2024;59(8):1154-1160. DOI: 10.1038/s41409-024-02291-6
More about...
Your opinion matters
21 votes - 19 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox